ISL exhibits significant pharmacological effects on the deterioration of diabetic nephropathy by reducing inflammation and oxidative stress associated with its direct binding to Sirtuin 1 (SIRT1), the inhibition of mitogen-activated protein kinase (MAPK), and the induction of Nrf-2 signaling [25]. Here, SIRT1 is linked to diabetic kidney disease.